

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 April 2001 (12.04.2001)

PCT

(10) International Publication Number
WO 01/25793 A3

(51) International Patent Classification⁷: **G01N 33/68,**
C07K 14/415, A61P 37/08

(21) International Application Number: **PCT/GB00/03760**

(22) International Filing Date: **2 October 2000 (02.10.2000)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
9923306.6 1 October 1999 (01.10.1999) **GB**

(71) Applicant (for all designated States except US): **ISIS IN-
NOVATION LIMITED [GB/GB];** Ewert House, Ewert
Place, Oxford OX2 7BZ (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ANDERSON,**
Robert, Paul [GB/GB]; Molecular Immunology, Nuffield
Dept of Medicine, Room 7604, Level 7, John Radcliffe

Hospital, Headington, Oxford OX3 9DU (GB). **HILL,**
Adrian, Vivian, Sinton [IE/GB]; Wellcome Trust Centre
for Human Genetics, University of Oxford, Roosevelt
Drive, Oxford OX3 7BN (GB). **JEWELL, Derek, Parry**
[GB/GB]; Gastroenterology Unit, Gibson Building, Rad-
cliffe Infirmary, Woodstock Road, Oxford OX2 6HE (GB).


(74) Agents: **IRVINE, Jonquil, Claire et al.; J.A. Kemp & Co.,**
14 South Square, Gray's Inn, London WC1R 5LX (GB).

(81) Designated States (national): **AE, AG, AL, AM, AT, AU,**
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): **ARIPO** patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), **Eurasian**
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), **European**
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), **OAPI** patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: **DIAGNOSIS OF COELIAC DISEASE USING A GLIADIN EPITOPE**



(57) Abstract: A method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising : (a) contacting a sample from the host with an agent selected from (i) the epitope comprising sequence which is : SEQ ID NO : 1 or 2, or an equivalent sequence from a naturally occurring homologue of the gliadin represented by SEQ ID NO : 3, (ii) an epitope comprising sequence comprising : SEQ ID NO : 1, or an equivalent sequence from a naturally occurring homologue of the gliadin represented by SEQ ID NO : 3, which epitope is an isolated oligopeptide derived from a gliadin protein, (iii) an analogue of (i) or (ii) which is capable of being recognised by a T cell receptor that recognises (i) or (ii), which in the case of a peptide analogue is not more than 50 amino acids in length, or (iv) a product comprising two or more agents as defined in (i), (ii) or (iii), and (b) determining *in vitro* whether T cells in the sample recognise the agent; recognition by the T cells indicating that the individual has, or is susceptible to, coeliac disease. Therapeutic compositions which comprise the epitope and gliadin proteins which do not cause coeliac disease are also provided.



Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(88) Date of publication of the international search report:

23 August 2001